Advertisement
UK markets close in 22 minutes

  • FTSE 100

    8,140.10
    +61.24 (+0.76%)
     

  • FTSE 250

    19,820.54
    +218.56 (+1.11%)
     

  • AIM

    755.23
    +2.11 (+0.28%)
     

  • GBP/EUR

    1.1664
    +0.0007 (+0.06%)
     

  • GBP/USD

    1.2460
    -0.0051 (-0.41%)
     

  • Bitcoin GBP

    51,038.53
    +193.73 (+0.38%)
     

  • CMC Crypto 200

    1,330.39
    -66.15 (-4.74%)
     

  • S&P 500

    5,104.77
    +56.35 (+1.12%)
     

  • DOW

    38,204.34
    +118.54 (+0.31%)
     

  • CRUDE OIL

    83.60
    +0.03 (+0.04%)
     

  • GOLD FUTURES

    2,345.40
    +2.90 (+0.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,165.17
    +247.89 (+1.38%)
     

  • CAC 40

    8,099.62
    +82.97 (+1.04%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

AstraZeneca's Brilinta fails in peripheral artery disease trial

Reuters - UK Focus

LONDON, Oct (HKSE: 3366-OL.HK - news) 4 (Reuters) - AstraZeneca (NYSE: AZN - news) said on Tuesday its heart drug Brilinta failed to show any benefit over an existing medicine in treating peripheral artery disease (PAD) in a large-scale clinical trial.

The company said it was disappointed that the drug, which is used to treat heart attack patients, had not been successful for PAD sufferers.

"We are disappointed that the EUCLID trial results showed Brilinta did not demonstrate a benefit over clopidogrel in this specific symptomatic PAD population," said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca. (Reporting by Paul Sandle; editing by Kate Holton)